Allergan Successfully Completes Tobira Therapeutics Acquisition - Acquisition Adds Global Rights to Highly Differentiated Compounds to Treat Multi-Factorial Elements of NASH - - Cenicriviroc...
Cenicriviroc Significantly Improved Fibrosis without Worsening of NASH at One Year Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on...
Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira PR Newswire DUBLIN, and SOUTH SAN FRANCISCO, Calif...
Biotechs with Key Corporate Developments PR Newswire NEW YORK, October 3, 2016 NEW YORK, October 3, 2016 /PRNewswire/ -- Performing clinical trials is an essential research tool for progressing...
Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share is Fair to Shareholders...
TOBIRA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Tobira Therapeutics, Inc. (TBRA) Over the Proposed Sale of the Company to Allergan plc PR Newswire NEW YORK...
Biotechnology Companies Reaching New Milestones PR Newswire NEW YORK, September 22, 2016 NEW YORK, September 22, 2016 /PRNewswire/ -- Transparency Market Research published a report on the...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Tobira Therapeutics, Inc. (“Tobira”) (NASDAQ:TBRA) stock prior to September...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.